Giuseppe Saltalamacchia

Giuseppe Saltalamacchia

Auto-generated profile, based on publicly available information

Giuseppe Saltalamacchia

Medical Oncology and Hematology Unit, Humanitas Research Hospital IRCCS , Rozzano, MI 20089

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2026 in The Oncologist
Verified
Journal Article
Open access
RTRosalba Torrisi
Rosalba Torrisi
FGFederica Giugliano
Federica Giugliano
LGLaura Giordano
Laura Giordano
GSGiuseppe Saltalamacchia
Giuseppe Saltalamacchia
FJFlavia Jacobs
Flavia Jacobs
EMelisabetta munzone
elisabetta munzone
Patients and methods: we retrospectively collected data of patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i) aiming to describe the patterns of post-progression outcomes. Results: Among 452 evaluable patients 325 were treated in the first-line setting. Median progression-free survival (mPFS) was 22.8 months overall and 29.7 months in patients treated in first-line setting. Factors associated with outcomes in multivariate analysis were the line of CDK4/6i therapy, de novo vs recurrent disease, visceral vs bone-only metastases, and primary endocrine resistance. A total of 300 patients progressed and 250 overall and 156 in the first-line cohort received a subsequent treatment. Visceral progression and CDK4/6i duration <12 months were associated with a higher likelihood of receiving anthracycline or taxanes (AT) as compared to ET ±everolimus (EET). Post-progression PFS (PPFS) and post-progression OS (PPOS) were statistically significantly better with EET and capecitabine (C) over AT overall and in patients with visceral progression. Multivariate analysis confirmed a significant advantage for EET and C, while visceral progression retained a significant impact only on PPOS. After progression to the first post-CDK4/6i treatment C obtained a significant better PPOS as compared to other treatments. Conclusion: We showed in a large real-world series that most patients with HR+/HER2− ABC failing CDK4/6i and ET unselected for the occurrence of molecular mutations retain endocrine sensitivity and may benefit of a subsequent ET ± a targeted therapy delaying the need for chemotherapy regardless of site of progression and prior CDK4/6i therapy duration.